Panthera began dosing volunteers in AstraZeneca’s phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19 at its sites in Preston, North Manchester and North London Kumar Jeetendra | January 5, 2021 Panthera’s clinical trial sites in Preston, North Manchester and North London began dosing volunteers in the Phase III PROVENT trial which will evaluate AstraZeneca’s long-acting antibody combination, AZD7442, for the potential prevention of COVID-19. The double-blind, placebo-controlled trial will include adult volunteers who have no history of COVID-19 and have an increased risk of infection, …
